资讯
A multicenter French study led by Rennes University Hospital reports potential benefits of glucagon-like peptide-1 receptor ...
Most people have likely heard about the new weight-loss and diabetes management drugs called Ozempic and Mounjaro, which are ...
New research reveals that GLP-1 receptor agonists significantly lower mortality risk in older cancer patients with type 2 ...
Glucagon-like peptide-1 (GLP-1) receptor agonists show promise in reducing cancer risk among patients with obesity, particularly for endometrial, ovarian, and meningioma cancers.
Tennis legend Serena Williams, throughout her illustrious career, has consistently defied conventional notions of femininity ...
Longer-term studies will be needed to track whether per-patient costs might drop over time with continued use of the meds.
People with obesity who take weight loss and diabetes drugs like Ozempic and Mounjaro could face a lower risk of cancer compared to those with obesity who do not. Looking at 14 cancers, of which 13 ...
GLP-1 receptor agonists show promise in treating hidradenitis suppurativa, offering significant symptom relief and improved ...
2 天on MSN
Serena Williams reveals she uses GLP-1 weight loss drug Zepbound: 'I just could never get ...
Serena Williams has revealed that she's taking a GLP-1 injectable weight loss treatment, in addition to her health regimen.
This retrospective cohort study found that taking glucagon-like peptide-1 receptor agonists (GLP-1RAs) was associated with a reduced overall risk of cancer, including lower risks of endometrial, ...
5 天
HealthDay on MSN26.5 Percent of Adults With Diabetes Used GLP-1 RA Injectables in 2024
In 2024, 26.5% of adults with diagnosed diabetes used glucagon-like peptide 1 receptor agonist (GLP-1 RA) injectables.
A new imaging approach reveals how dual agonist drugs like tirzepatide act on the pancreas and brain to regulate blood sugar and appetite.
一些您可能无法访问的结果已被隐去。
显示无法访问的结果